Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma.
Uchiyama
Michihiro
M
Tamai
Yotaro
Y
Ikeda
Takashi
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use*; D018890:Chemoprevention; D003520:Cyclophosphamide; D004317:Doxorubicin / Q000031:analogs & derivatives; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000517:prevention & control / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D016896:Treatment Outcome; D014750:Vincristine; D014775:Virus Activation / Q000187:drug effects*
D000998:Antiviral Agents; C413685:entecavir; D014750:Vincristine; D006147:Guanine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone